Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

BACKGROUND: Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis. METHODS: In an open-label, phase 3, randomized, controlled trial involving persons with newly diagnosed pulmonary tuberculosis f...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:N Engl J Med
Päätekijät: Dorman, Susan E., Nahid, Payam, Kurbatova, Ekaterina V., Phillips, Patrick P.J., Bryant, Kia, Dooley, Kelly E., Engle, Melissa, Goldberg, Stefan V., Phan, Ha T.T., Hakim, James, Johnson, John L., Lourens, Madeleine, Martinson, Neil A., Muzanyi, Grace, Narunsky, Kim, Nerette, Sandy, Nguyen, Nhung V., Pham, Thuong H., Pierre, Samuel, Purfield, Anne E., Samaneka, Wadzanai, Savic, Radojka M., Sanne, Ian, Scott, Nigel A., Shenje, Justin, Sizemore, Erin, Vernon, Andrew, Waja, Ziyaad, Weiner, Marc, Swindells, Susan, Chaisson, Richard E.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282329/
https://ncbi.nlm.nih.gov/pubmed/33951360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2033400
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia